Lenacapavir
-
Zambia receives first US-funded Lenacapavir shipment for HIV prevention
Lenacapavir has demonstrated almost 100% efficacy in preventing HIV infection in clinical trials, giving Zambia an additional prevention option alongside existing HIV services.
-
Gauteng receives 28,593 Lenacapavir packs as demand for HIV prevention rises
The replenishment will restore supplies at facilities in Tshwane, Johannesburg and Sedibeng that experienced temporary shortages after demand exceeded initial projections following the programme’s rollout in June 2026.
-
South Africa begins historic twice-yearly injectable HIV prevention rollout
The Department of Health has begun distributing the injectable through an initial network of 360 health facilities located in high-burden districts.
-
Benue State rolls out injectable HIV PrEP Lenacapavir in Nigeria
The launch brings together national and international health stakeholders who are supporting Nigeria’s broader HIV response strategy.
-
South Africa secures first doses of twice-yearly HIV injectable Lenacapavir
The South African Health Products Regulatory Authority officially approved Lenacapavir, branded as Sunlenca, on October 27, 2025, making South Africa the first African country to authorize this innovation.
-
Nigeria commences Lenacapavir rollout for HIV prevention
Lenacapavir complements existing prevention methods such as oral pre-exposure prophylaxis and long-acting injectable cabotegravir.
-
Kenya begins nationwide rollout of revolutionary HIV prevention injectable Lenacapavir
The initial rollout will target 152 health facilities across 15 high-burden counties, following a carefully structured, phased approach.
-
Rwanda to roll out long-acting HIV prevention injection Lenacapavir by the end of 2026
The introduction of lenacapavir will expand rather than replace current prevention methods available in Rwanda.